While the novel payment models for expensive cell and gene therapies have been effective, they need to continue evolving, said Joe DePinto, MBA, of McKesson.
As BioMarin turns to commercialization of Roctavian, we will likely hear more about how warranties could help gene therapies overcome payer reimbursement hurdles.